A detailed history of Mackenzie Financial Corp transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Mackenzie Financial Corp holds 1,486 shares of KRYS stock, worth $238,993. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,486
Previous 1,357 9.51%
Holding current value
$238,993
Previous $249,000 8.43%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$174.7 - $213.66 $22,536 - $27,562
129 Added 9.51%
1,486 $270,000
Q1 2024

May 10, 2024

BUY
$108.01 - $179.35 $146,569 - $243,377
1,357 New
1,357 $241,000

Others Institutions Holding KRYS

About Krystal Biotech, Inc.


  • Ticker KRYS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,664,300
  • Market Cap $4.13B
  • Description
  • Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...
More about KRYS
Track This Portfolio

Track Mackenzie Financial Corp Portfolio

Follow Mackenzie Financial Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mackenzie Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Mackenzie Financial Corp with notifications on news.